

### REMARKS

Claims 4-6 were pending in this application. Claims 5 and 6 are canceled without prejudice. New claims 7-19 have been added. Support for the new claims may be found throughout the specification and claims as originally filed, for example, at least in paragraphs [0010], [0024], [0063], and [0068] through [0073] of the published application (*i.e.*, U.S. Pub. No. 2005/0027107). No new matter is introduced by these amendments.

After entry of this Amendment, **claims 4 and 7-19 are pending in this application.** Consideration of the pending claims is requested.

#### Restriction Requirement

The Office contends that the pending claims are directed to four “distinct” inventions and has required restriction to one alleged invention under 35 U.S.C. 121. The four Groups provided by the Office are:

- |                             |   |
|-----------------------------|---|
| Group I (claim 4)           | drawn to a method for determining whether a composition modulated Pin1 activity;  |
| Group II (claim 5 in part)  | drawn to a method for treating a cell proliferative disorder in a subject, comprising administering an amount of Pin1 to induce mitotic arrest and nuclear fragmentation;               |
| Group III (claim 5 in part) | drawn to a method for treating a cell proliferative disorder in a subject, comprising administering an amount of PIN1 inhibitor to induce mitotic arrest and nuclear fragmentation; and |
| Group IV (claim 6)          | drawn to a method for treating a cell proliferative disorder in a subject, comprising administering an amount of PIN1 enhancer to block the cell in G2.                                 |

Applicants traverse the restriction requirement, at least, because the claims of each Group have a common thread, Pin1. Thus, a search for Pin1 will inevitably uncover prior art pertinent to any combination or all of the Groups I-IV claims. Nevertheless, solely to expedite prosecution of this application, Applicants provisionally elect the Group I claims (*i.e.*, claim 4),

drawn to a method for determining whether a composition modulated Pin1 activity, and cancel (without prejudice) the claims of Groups II-IV.

Applicants reserve the right to continue traversal of the restriction between the aforementioned groups in this or a continuing application. Applicants further reserve the right to pursue the non-elected groups in one or more divisional applications and/or to pursue the claims as originally filed, or similar claims, in this or one or more subsequent patent applications.

*Request to Correct the Record*

With regard to Group II (claim 5 in part), Applicants note that the term “inhibitor” in now-canceled claim 5 modified each of the terms “Pin1” and “PIN1”; accordingly, claim 5 should have been interpreted to read, in relevant part, “. . . administration of a Pin1 [inhibitor] or PIN1 inhibitor . . .” Thus, even if drawn to a distinct invention (which is not admitted), Group II should have been drawn to a method for treating a cell proliferative disorder in a subject, comprising administering an amount of Pin1 *inhibitor* to induce mitotic arrest and nuclear fragmentation (emphasis added). Applicants respectfully ask the Examiner to correct the restriction requirement record.

### CONCLUSION

Substantive examination of the pending claims is respectfully requested. The Examiner is invited to call the undersigned if the Examiner believes that a telephone interview would facilitate substantive examination of this application.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By Debra A. Gordon  
Debra A. Gordon, Ph.D.  
Registration No. 54,128

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446